Tradestie Institutional Equity Comparison Engine
MNOV vs NERV โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
MNOV Overall Edge
MNOV Captures Institutional Edge (4โ0 Pillars ยท 7โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Medicinova, Inc. (MNOV) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, MNOV trades at 8.5x Forward P/E with -1232.2% operating margin (+12.4% YoY revenue) versus NERV at 11.2x Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, MNOV sits in UNCLASSIFIED (50th %ile IV; Dealer Gamma Walls on Pro) against NERV sits in BREAKDOWN (100th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
MNOV
MNOV 8.5x vs NERV 11.2x Fwd P/E
Growth & Margin Winner
MNOV
Op Margin -1232.2% vs 0.0% ยท YoY +12.4% vs +0.0%
Momentum & Technical Winner
MNOV
1Y -8.4% vs -53.5% ยท 52W Pos 3% vs 1%
Options & Structure Winner
MNOV
UNCLASSIFIED (50th %ile IV) vs BREAKDOWN (100th %ile IV)
MNOV
NASDAQ
Medicinova, Inc.
Pharmaceutical Preparations
$1.31
+3.15% 1D
Market Cap
$65.1M
1M Return
-7.09%
1Y Return
-8.39%
Forward P/E
8.5x
Unified AI Score
50.2 / 100
HOLD
Tech 47.0
Fund 46.0
Flow 63.0
Mom 64.0
NERV
NASDAQ
Minerva Neurosciences, Inc
Pharmaceutical Preparations
$2.00
-5.66% 1D
Market Cap
$105.7M
1M Return
-16.67%
1Y Return
-53.49%
Forward P/E
11.2x
Unified AI Score
43.3 / 100
HOLD
Tech 30.0
Fund 51.0
Flow 65.0
Mom 60.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
MNOV -8.39%
NERV -53.49%
Spread: +45.1 pp (MNOV Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
MNOV TTM Op. Margin: -1232.2%
NERV TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MNOV vs NERV. Trailing 12-month operating profitability (MNOV -1232.2% vs NERV 0.0%) and valuation multiples (MNOV 8.5x vs NERV 11.2x Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | MNOV | NERV | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $65.1M | $105.7M | Larger Scale | NERV |
| Trailing P/E Ratio Valuation | 8.5x | 11.2x | Lower Multiple | MNOV |
| Forward P/E Ratio Valuation | 8.5x | 11.2x | Lower Multiple | MNOV |
| Revenue Growth (YoY) Growth | +12.4% | +0.0% | Higher Growth | MNOV |
| Operating Margin (TTM) Profitability | -1232.2% | 0.0% | Higher Margin | NERV |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -24.8% | -675.1% | Higher ROE | MNOV |
| 52-Week Range Position Momentum | 3% ($1โ$4) | 1% ($2โ$9) | Stronger Trend | MNOV |
| Beta / 30D Volatility Risk Regime | 0.59ฮฒ ยท 38% Vol | 1.63ฮฒ ยท 76% Vol | Lower Realized Risk | MNOV |
| Unified Institutional Score Composite Signal | 50.2 / 100 (HOLD) | 43.3 / 100 (HOLD) | Higher Composite | MNOV |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full MNOV vs NERV Buy Guide
MNOV
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
50th %ile
IV Regime
Balanced (25thโ60th %ile)
NERV
BREAKDOWN
148d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
100th %ile
IV Regime
Extreme (>80th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither MNOV nor NERV registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.